Author:
McGee J.,Bookman M.,Harter P.,Marth C.,McNeish I.,Moore K.N.,Poveda A.,Hilpert F.,Hasegawa K.,Bacon M.,Gatsonis C.,Brand A.,Kridelka F.,Berek J.,Ottevanger N.,Levy T.,Silverberg S.,Kim B.-G.,Hirte H.,Okamoto A.,Stuart G.,Ochiai K.
Funder
Astra Zeneca UK Limited
Bristol-Myers Squibb Company
Clovis Oncology Inc.
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
Pharma Mar, S.A.
TESARO, Inc.
Zeria Pharmaceutical Co., Ltd.
Reference87 articles.
1. First-Line Therapy in Ovarian Cancer Trials;Thigpen;Int J Gynecol Cancer,2011
2. Staging classification for cancer of the ovary, fallopian tube, and peritoneum;Prat;Int J Gynaecol Obstet,2014
3. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer;Vergote;N Engl J Med,2010
4. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial;Kehoe;Lancet,2015
5. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study;Winter;J Clin Oncol,2007
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献